Related Experiment Video

Updated: May 26, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

Management of dyslipidemia in HIV-infected patients

Carlos D Malvestutto1, Judith A Aberg

  • 1Division of Infectious Diseases & Immunology, Bellevue Hospital Center, New York University School of Medicine, NY, USA.

Clinical Lipidology
|January 5, 2012
PubMed

Insights

Antiretroviral therapy improves survival for people with HIV, but increases coronary heart disease risk due to dyslipidemia. Managing this complex condition is challenging due to drug interactions.

Area of Science:

  • Medical Science
  • Cardiology
  • Infectious Diseases

Background:

  • Antiretroviral therapy (ART) has significantly improved survival rates for individuals with human immunodeficiency virus (HIV).
  • Increased longevity in the HIV-positive population has led to a rise in non-communicable diseases, particularly coronary heart disease (CHD).
  • Dyslipidemia is a common and complex comorbidity in HIV-infected individuals, contributing to cardiovascular risk.

Purpose of the Study:

  • To explore the multifaceted nature of dyslipidemia in HIV-infected individuals.
  • To highlight the challenges in managing dyslipidemia within this population.
  • To emphasize the need for effective cardiovascular risk reduction strategies.

Main Methods:

  • Review of current literature on HIV, dyslipidemia, and cardiovascular disease.
  • Analysis of contributing factors to dyslipidemia in HIV, including viral, genetic, and treatment-related aspects.
  • Examination of challenges in managing dyslipidemia, focusing on drug-drug interactions between ART and lipid-lowering agents.

Main Results:

  • Dyslipidemia in HIV is multifactorial, influenced by the virus, host genetics, and ART-induced metabolic changes.
  • Effective management of dyslipidemia is crucial for reducing cardiovascular risk in aging HIV-positive individuals.
  • Significant challenges exist in managing dyslipidemia due to potential interactions between ART and lipid-lowering medications.

Conclusions:

  • Managing dyslipidemia in HIV-infected individuals requires a comprehensive approach considering multiple contributing factors.
  • Addressing ART-drug interactions is essential for safe and effective lipid management.
  • Further research is needed to optimize cardiovascular risk management strategies for this growing population.

More Related Videos

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies07:10

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies

Published on: January 7, 2019

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Sexually Transmitted Infections01:26

Sexually Transmitted Infections

Sexually transmitted infections (STIs) are diseases transmitted primarily through unsafe sexual interactions. Bacteria, viruses, or parasites cause them and can result in severe health complications if untreated.ChlamydiaThe bacterium Chlamydia trachomatis is responsible for the disease Chlamydia, the most common STI in the United States. This peculiar pathogen requires human cells to reproduce, residing intracellularly. The initial infection often goes unnoticed because it typically does not...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...